Clareo Health | A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female patients that have signed informed consent and are \>/= 40 years of age.
Patients with stable COPD according to GOLD 2011.
Patients with a post-bronchodilator FEV1 of \>/= 30% and \< 80% predicted and a post-bronchodilator FEV1/FVC \<0.70.
Current or ex-smokers who have a smoking history of at least 10 pack years.
Patients with an mMRC grade 2 or greater.
You may not be if
Patients with Type I or uncontrolled Type II diabetes - Patients with a history of long QT syndrome or whose QTc measured at Visit 101 (Fridericia method) is prolonged (\>450 ms for males and females) and confirmed by a central assessor. (These patients should not be re-screened.)
Patients who have a clinically significant ECG abnormality at Visit 101 or Visit 102. (These patients should not be re-screened.)
Patients with a history of malignancy of any organ system, treated or untreated, within the last five years.
Patients with narrow-angle glaucoma, BPH or bladder-neck obstruction or moderate-severe renal impairment or urinary retention.
Patients who had a COPD exacerbation within 6 weeks prior to screening.
Patients who have a respiratory tract infection within 4 weeks prior to screening.
Patients requiring long term oxygen therapy prescribed for more than 12 hr per day.
Patients with a history of asthma. 8. Patients with an onset of respiratory symptoms, including COPD diagnosis, prior to age 40 years.
Patients with a blood eosinophil count of greater than 600 mm/3 during run-in.
Patients with concomitant pulmonary disease.
Patients with a diagnosis of alpha-1 anti-trypsin deficiency.
Patients with active pulmonary tuberculosis.
Patients in the active phase of a pulmonary rehabilitation programme.
